Does lipid-lowering therapy slow progression of chronic kidney disease?
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Use of statins is associated with modest preservation of eGFR.
“In support of this hypothesis are data suggesting that use of statins is associated with modest preservation of eGFR,11”
From Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes (2019) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Tonelli, M., Moy, L., Sacks, F. M., Kiberd, B., Curhan, G., & for the Cholesterol and Recurrent Events (CARE) Trial Investigators (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00010 · Cited by 278 · see citing works
Fibrate‐induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Broeders, N., Knoop, C., Antoine, M., Tielemans, C., & Abramowicz, D. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.12.1993 · Cited by 163 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Frazier, R., Mehta, R., Cai, X., Lee, J., Napoli, S., Craven, T., Tuazon, J., Safdi, A., Scialla, J., Susztak, K., et al. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2018.09.006 · Cited by 63 · see citing works
- Authors
- Wheeler, D. C.
- Affiliations
- The Royal Free Hospital (GB)
- Corresponding author
- Wheeler, David C.
- ORCID
- Wheeler, David C.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2004-11
- Volume
- 44
- Issue
- 5
- Pages
- 917-920
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W2020173463
- Cited by
- 11
- References
- 2
- Citations by year
- 2026: 1 · 2018: 1
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Kidney Diseases (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- lipid-lowering therapy, chronic kidney disease progression, dyslipidemia, lipid hypothesis, glomerulosclerosis, tubulointerstitial fibrosis, high-fat diet, kidney injury
- MeSH terms
- Animals, Hypolipidemic Agents, Chronic Disease, Humans, Hyperlipidemias, Kidney Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
